Cytotoxic chemotherapy may overcome the development of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) therapy. Issue 3 (September 2015)

• Record Type: Journal Article
• Authors: Kanda, Shintaro; Horinouchi, Hidehito; Fujiwara, Yutaka; Nokihara, Hiroshi; Yamamoto, Noboru; Sekine, Ikuo; Kunitoh, Hideo; Kubota, Kaoru; Tamura, Tomohide; Ohe, Yuichiro
• Is Part Of: Lung cancer. Volume 89:Issue 3(2015:Sep.)
• Page Start: 287
• Page End: 293
• Publication Date: 2015-09
• Subjects: Lungs -- Cancer -- Periodicals; Lung Neoplasms -- Abstracts; Lung Neoplasms -- Periodicals; Poumons -- Cancer -- Périodiques; Lungs -- Cancer; Periodicals; Electronic journals; Electronic journals; 616.99424
• DOI: 10.1016/j.lungcan.2015.06.016
• Languages: English
• ISSNs: 0169-5002

Abstract

<abstract abstract-type="author-highlights" id="abs0005"> <title id="sect0005">Highlights</title> <sec> <p id="spar0005"> <list id="lis0005"> <list-item id="lsti0005"> <label></label> <p id="par0005">A phase II trial of gefitinib with inserted cisplatin plus docetaxel therapy.</p> </list-item> <list-item id="lsti0010"> <label></label> <p id="par0010">Patients with advanced non-small cell lung cancer harboring <italic>EGFR</italic> mutations were enrolled.</p> </list-item> <list-item id="lsti0015"> <label></label> <p id="par0015">The median progression free survival (PFS) was 19.5 months and 5-year PFS rate was 22.0%.</p> </list-item> <list-item id="lsti0020"> <label></label> <p id="par0020">The median survival time was 48.0 months and 5-year survival rate was 36.5%.</p> </list-item> <list-item id="lsti0025"> <label></label> <p id="par0025">The insertion of chemotherapy might prevent the acquired resistance to EGFR-TKIs.</p> </list-item> </list> </p> </sec> </abstract>